Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and (90)Y-DOTA

Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited the use of PRIT with an anti-CD45 antibody (Ab)-str...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Cancer Ther
Glavni autori: Orozco, Johnnie J., Kenoyer, Aimee L., Lin, Yukang, O’Steen, Shyril, Guel, Rosario, Nartea, Margaret E., Hernandez, Alexandra H., Hylarides, Mark D., Fisher, Darrell R, Balkin, Ethan R., Hamlin, Donald K., Wilbur, D. Scott, Orcutt, Kelly D., Wittrup, K. Dane, Green, Damian J., Gopal, Ajay K., Till, Brian G., Sandmaier, Brenda, Press, Oliver W., Pagel, John M.
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7718432/
https://ncbi.nlm.nih.gov/pubmed/33082277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0306
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items